Dati della Fase 2 di ERLEADA®▼(apalutamide) più trattamento di deprivazione androgenica in seguito a prostatectomia radicale in pazienti affetti da tumore della prostata localizzato ad alto rischio mostrano un tasso del 100 percento di assenza di recidiva biochimica più di due anni dopo l'intervento
May 09, 2024 05:12 ET
|
Janssen Cilag International NV
Lo studio evidenzia l'opportunità di intensificare il trattamento in tale popolazione poiché approssimativamente il 50 percento di pazienti con tumore della prostata localizzato ad alto rischio...
Données de phase 2 pour ERLEADA®▼(apalutamide) en association avec un traitement par privation androgénique après une prostatectomie radicale chez des patients atteints d’un cancer de la prostate localisé à haut risque : un taux de survie sans récidive biochimique de 100 pour cent plus de deux ans après l’intervention chirurgicale
May 09, 2024 05:11 ET
|
Janssen Cilag International NV
L’étude met en évidence la possibilité d’intensifier le traitement pour cette population, puisque près de 50 pour cent des patients atteints d’un cancer de la prostate localisé à haut risque (CPLHR)...
TAR-210 results show 90 percent recurrence-free survival and 90 percent complete response in patients with high-risk and intermediate-risk non-muscle-invasive bladder cancer, respectively
May 05, 2024 14:39 ET
|
Janssen Cilag International NV
Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor (FGFR) alterations1 BEERSE, BELGIUM, May 05,...
Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer shows 100 percent biochemical free recurrence rate more than two years post-surgery
May 03, 2024 12:39 ET
|
Janssen Cilag International NV
Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate cancer (HRLPC) experience disease recurrence...
TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
May 03, 2024 11:53 ET
|
Janssen Cilag International NV
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus...
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease
May 01, 2024 06:55 ET
|
Janssen Cilag International NV
Media contact:Sophie DaneauSdaneau@its.jnj.com+33 6 3178 8798Investor contact:Raychel Kruperinvestor-relations@its.jnj.com For European and UK medical and trade media only For immediate...
Janssen to adopt Johnson & Johnson brand as the Company celebrates 100 years of operating in the UK
May 01, 2024 03:00 ET
|
Janssen Cilag International NV
Johnson & Johnson marks new era in the UK with updated visual identity High Wycombe, UK, May 01, 2024 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced it is updating its brand and...
Johnson & Johnson recibe la opinión positiva del CHMP para RYBREVANT®▼ (amivantamab) en combinación con quimioterapia para el tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico (CPNM) avanzado con mutaciones activadoras de inserción en el exón 20 del receptor del EGFR
April 30, 2024 12:28 ET
|
Janssen Cilag International NV
Esta opinión positiva del CHMP sitúa a amivantamab como una nueva opción de tratamiento y como el primer anticuerpo biespecífico totalmente humano dirigido contra los receptores del factor de...
Johnson & Johnson riceve il parere positivo del CHMP per RYBREVANT®▼ (amivantamab) in combinazione con la chemioterapia per il trattamento di prima linea di pazienti con carcinoma polmonare non a piccole cellule in stadio avanzato con mutazioni attivanti da inserzione nell’esone 20 dell’EGFR
April 30, 2024 12:20 ET
|
Janssen Cilag International NV
Il parere positivo del CHMP stabilisce che amivantamab rappresenta una nuova opzione, nonché il primo anticorpo bispecifico EGFR-MET completamente umano, nel trattamento di prima linea del NSCLC con...
Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
April 26, 2024 07:55 ET
|
Janssen Cilag International NV
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC ...